To meet the needs of patients, we must reimagine health system financing models. The social health insurance model, which relies on employment-based contributions, is not sustainable during times of economic downturn, rising unemployment and ageing populations. Falling back on out-of-pocket payments only stands to worsen the health outcomes of the most vulnerable. While no single model will solve all the problems, governments should lean toward providing universal access to healthcare to broaden healthcare accessibility and reduce the burden on patients. For more on reimagining healthcare financing for the future, read our report in partnership with Economist Impact.
Financing the future of healthcare
To meet the needs of patients, we must reimagine health system financing models. The social health insurance model, which relies on employment-based contributions, is not sustainable during times of economic downturn, rising unemployment and ageing populations. Falling back on out-of-pocket payments only stands to worsen the health outcomes of the most vulnerable. While no single model will solve all the problems, governments should lean toward providing universal access to healthcare to broaden healthcare accessibility and reduce the burden on patients. For more on reimagining healthcare financing for the future, read our report in partnership with Economist Impact.
Related items
:focal())
News
20 May 2026
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Position Paper
19 May 2026
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.